Navigation Links
Even Tiny Breast Tumors May Need Aggressive Treatment
Date:12/17/2007

For a subset of cancer types, treatment needs to be much tougher than is typically done, study finds

MONDAY, Dec. 17 (HealthDay News) -- Even if they're very small (1 centimeter or less), certain kinds of breast cancer tumors can still be aggressive and require maximum therapy, U.S. researchers say.

A team at the Mayo Clinic in Jacksonville, Fla., found that outcomes for women with HER2 positive (HER2+) and triple negative (HER2- and ER/PR-) tumors that have not spread to the lymph nodes may not depend on tumor size alone.

About 15 percent to 20 percent of breast cancers are HER2+, and about 10 percent to 15 percent are triple negative.

"This is a small study, and so we can't make treatment recommendations from it, but it appears that biology and not only size matters when it comes to selecting therapy for small, invasive tumors," lead researcher Dr. Surabhi Amar, a fellow in hematology/oncology, said in a prepared statement.

Amar noted there are no definitive treatment guidelines for breast cancer tumors less than one centimeter in size, because most studies include women with larger tumors or with breast cancer that's spread to the lymph nodes.

"We just don't have extensive data on tumors this small, so treatment becomes a matter of physician discretion," Amar said.

The study included 401 breast cancer patients: 350 with HER2 negative/ER/PR+ tumors; 27 with HER2+ tumors; and 24 with triple negative tumors. The women were followed for an average of about three years.

The researchers found that women with HER2+ and triple negative cancers were more likely (92 percent and 91 percent, respectively) to have grade 2 and 3 tumors than women with HER2 negative/ER/PR+ cancer (36 percent). Tumors are graded from 1 to 3. Higher grade tumors are more likely to grow faster and be difficult to treat.

The study also found that cancer recurrence was more common in women with HER2+ tumors (7.4 percent) and triple negative tumors (12.5 percent) than in women with HER2 negative/ER/PR+ tumors (1.3 percent).

The overall outcome for all the women with these small, lymph-node-negative tumors was excellent -- overall survival was 97.4 percent and disease-free survival 95.1 percent. One of the 24 patients with triple negative cancer died, none of the 24 women with HER2+ died, and one of the 219 women with HER2 negative/ER/PR+ cancer died.

The study findings suggest that women with small HER2+ and triple negative breast tumors should receive as much treatment as possible in order to prevent cancer relapse, Amar said.

But that doesn't appear to be happening. The study found that only 35 percent of women with triple negative cancers and 28 percent of those with HER2+ tumors received adjuvant chemotherapy (chemotherapy after surgery).

The study was to be presented Dec. 16 at the San Antonio Breast Cancer Symposium.

More information

The American Cancer Society has more about breast cancer.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Dec. 16, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: